Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells

Summary

This is a randomized phase II placebo controlled clinical trial. Active arm: Allogeneic Wharton's jelly derived MSCs (WJ-MSCs). Both groups will receive standard of care treatment for COVID (e.g. dexamethasone)

Timeline

Start

2021-06-14

Primary completion

2023-05-26

Completion

2023-05-26

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

Stopped (Enrollment): “DSMB advised discontinuing the study prematurely because recruitment goals were not achieved.”

release “Due to limited enrollment and early termination, no definitive conclusions regarding efficacy can be drawn.” nextcellpharma.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ProTrans	Cell therapy	1e+08 cells	Intravenous

Indications